Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5216737 | 0.81 | LMNA (0.30) | — | |
| SCHEMBL4591683 | 0.71 | BRD4 (0.46) | BRD4 | |
| SCHEMBL4591323 | 0.61 | DRD2 (0.39) | BRD4 | |
| SCHEMBL26743685 | 0.60 | — | — | |
| SCHEMBL31309701 | 0.59 | BRD4 (0.63) | BRD4 | |
| SCHEMBL11534030 | 0.56 | BRD4 (0.58) | BRD4 | |
| SCHEMBL11626062 | 0.56 | BRD4 (0.58) | BRD4 | |
| SCHEMBL23856649 | 0.55 | BRD4 (0.33) | BRD4 | |
| SCHEMBL30047460 | 0.55 | BRD4 (0.33) | BRD4 | |
| SCHEMBL8164815 | 0.55 | BRD4 (0.38) | BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7189736-B2 | Prodrugs of imidazopyridine derivatives | ALTANA PHARMA AG (DE) | 2007-03-13 | — | — | US | disclosed |
| EP-1303519-B1 | TRICYCLIC IMIDAZOPYRIDINES | ALTANA PHARMA AG (DE) | 2007-03-07 | — | — | EP | disclosed |
| US-7141567-B2 | Polysubstituted imidazopyridines as gastric secretion inhibitors | ALTANA PHARMA AG (DE) | 2006-11-28 | — | — | US | disclosed |
| EP-1313739-B1 | ALKYLATED IMIDAZOPYRIDINE DERIVATIVES | ALTANA PHARMA AG (DE) | 2006-07-05 | — | — | EP | disclosed |
| EP-1286993-B1 | IMIDAZOPYRIDIN-8-ONES | ALTANA PHARMA AG (DE) | 2006-06-07 | — | — | EP | disclosed |
| EP-1313740-B1 | PRODRUGS OF IMIDAZOPYRIDINE DERIVATIVES | ALTANA PHARMA AG (DE) | 2005-11-30 | — | — | EP | disclosed |
| US-6916825-B2 | Alkylated imidazopyridine derivatives | ALTANA PHARMA AG (DE) | 2005-07-12 | — | — | US | disclosed |
| US-6869949-B2 | Polysubstituted imidazopyridines as gastric secretion inhibitors | ALTANA PHARMA AG (DE) | 2005-03-22 | — | — | US | disclosed |
| US-20040214852-A1 | Polysubstituted imidazopyridines | ALTANA PHARMA AG (DE) | 2004-10-28 | — | — | US | disclosed |
| US-20040198764-A1 | Prodrugs of imidazopyridine derivatives | SENN-BILFINGER JORG (DE) | 2004-10-07 | — | — | US | disclosed |
| EP-1313739-A1 | ALKYLATED IMIDAZOPYRIDINE DERIVATIVES | ALTANA Pharma AG (DE) | 2003-05-28 | — | — | EP | disclosed |
| EP-1313740-A1 | PRODRUGS OF IMIDAZOPYRIDINE DERIVATIVES | ALTANA Pharma AG (DE) | 2003-05-28 | — | — | EP | disclosed |
| EP-1303519-A1 | TRICYCLIC IMIDAZOPYRIDINES | ALTANA Pharma AG (DE) | 2003-04-23 | — | — | EP | disclosed |
| WO-2001072748-A9 | IMIDAZOPYRIDIN-8-ONES | ALTANA PHARMA AG (DE) | 2003-04-10 | — | — | WO | disclosed |
| EP-1286993-A1 | IMIDAZOPYRIDIN-8-ONES | ALTANA Pharma AG (DE) | 2003-03-05 | — | — | EP | disclosed |
| WO-2002034749-A1 | POLYSUBSTITUTED IMIDAZOPYRIDINES AS GASTRIC SECRETION INHIBITORS | ALTANA PHARMA AG (DE) | 2002-05-02 | — | — | WO | disclosed |
| WO-2001072757-A1 | TRICYCLIC IMIDAZOPYRIDINES | ALTANA PHARMA AG (DE) | 2001-10-04 | — | — | WO | disclosed |
| WO-2001072754-A1 | ALKYLATED IMIDAZOPYRIDINE DERIVATIVES | ALTANA PHARMA AG (DE) | 2001-10-04 | — | — | WO | disclosed |
| WO-2001072748-A1 | IMIDAZOPYRIDIN-8-ONES | ALTANA PHARMA AG (DE) | 2001-10-04 | — | — | WO | disclosed |
| WO-2001072756-A1 | PRODRUGS OF IMIDAZOPYRIDINE DERIVATIVES | ALTANA PHARMA AG (DE) | 2001-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198764-A1 | Prodrugs of imidazopyridine derivatives | SI, CYP2E1, UGT1A1 | BRD4 2995/4885 |
| US-20040214852-A1 | Polysubstituted imidazopyridines | GIPR, VIP, SLC10A2 | BRD4 1054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.